Overview
Basal cell carcinoma (BCC) is the most common type of skin cancer, characterized by slow-growing, locally invasive tumors arising from basal cells in the epidermis. It rarely metastasizes but can cause significant local tissue destruction if left untreated 1.Diagnosis
Clinical appearance: Pearly nodules, telangiectatic vessels, ulceration, or pigmented lesions 1.
Dermatoscopy: Helps differentiate BCC from other skin lesions 1.
Biopsy: Histopathological examination confirms diagnosis 1.
Grading: Not typically used for BCC management, but differentiation between nodular, superficial, and morpheaform subtypes is important 1.Management
Primary treatment: Surgical excision (Mohs micrographic surgery often preferred for aggressive subtypes) 1.
Non-surgical options: Curettage and electrodesiccation, topical therapies (imiquimod, 5-fluorouracil) for superficial BCC 1.
Radiation therapy: Reserved for recurrent or inoperable cases 1.Special Populations
Immunosuppressed patients: No specific evidence in abstracts provided; however, caution is advised due to potential increased risk of aggressive subtypes 1.
Comorbidities: No specific management adjustments noted in provided abstracts 1.Key Recommendations
Confirm diagnosis through histopathological examination after biopsy 1.
Consider Mohs micrographic surgery for high-risk or aggressive BCC subtypes due to its precision in minimizing tissue removal 1 (Evidence: Moderate).
For superficial BCC, topical therapies like imiquimod or 5-fluorouracil can be effective alternatives to surgery 1 (Evidence: Moderate).
Monitor immunosuppressed patients closely due to potential for more aggressive disease behavior, though specific management adjustments are not detailed in current evidence 1 (Evidence: Expert opinion).References
1 Jedlowski PM, DuPont JP. Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system. Journal of the European Academy of Dermatology and Venereology : JEADV 2024. link